



AUG 07 2008

OFFICE OF INTELLECTUAL PROPERTY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/714,449-Conf. #9366
 Filing Date November 17, 2003
 First Named Inventor Lagunas
 Art Unit 1633
 Examiner Name S. Kaushal
 Attorney Docket Number 42597-193226

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Kastrup et al., "Direct Intramyocardial Plasmid Vascular Endothelial Growth Factor-A ₁₆₅ Gene Therapy in Patients with Stable Severe Angina Pectoris", JACC, 45(7), 2005, pp. 982-988	
	C2	Vera Janavel et al., "Plasmid-mediated VEGF gene transfer induced cardiomyogenesis and reduces myocardial infarct size in sheep", Gene Therapy, 2006, pp. 1-10	
	C3	Stewart/Cannon, "NORTHERN: A Prospective, Randomized, Double Blind, Placebo-Controlled Evaluation of Intramyocardial VEGF-165 Plasmid Gene Therapy in Patients with Refractory Angina", Transcatheter Cardiovascular Therapeutics conference, Cardiovascular Research Foundation, October 23, 2007, Abstract	
	C4	Lekas et al., Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation", Therapeutic neovascularization for ischaemic vascular disease, Current Opinion in Cardiology 21, pp. 376-383	

Examiner Signature /Sumesh Kaushal/ (09/29/2008) Date Considered